Antiangiogenic Agents in Cancer Therapy

  • Beverly A. Teicher

Part of the Cancer Drug Discovery and Development book series (CDD&D)

Table of contents

  1. Front Matter
    Pages i-xi
  2. Antiangiogenic Factors and Tumor Vasculature

    1. Front Matter
      Pages 1-1
    2. Zishan A. Haroon, Kevin G. Peters, Charles S. Greenberg, Mark W. Dewhirst
      Pages 3-21
    3. Eric Lartigau, Marcelle Guichard
      Pages 23-35
    4. Federico Bussolino, Alberto Mantovani
      Pages 37-50
    5. Chang W. Song, HeonJoo Park, Brian D. Ross
      Pages 51-64
    6. Diane R. Bielenberg, Isaiah J. Fidler
      Pages 77-91
    7. Israel Vlodavsky, Gerhard Christofori
      Pages 93-118
    8. M. Zamirul Hussain, Q. Perveen Ghani, John J. Feng, Thomas K. Hunt
      Pages 143-150
  3. Antiangiogenic Agents

    1. Front Matter
      Pages 151-151
    2. Jon I. Williams
      Pages 153-174
    3. Vincent Castronovo, Violetta Dimitriadou, Pierre Savard, Marc Rivière, Eric Dupont
      Pages 175-183
    4. David W. Dawson, Noël P. Bouck
      Pages 185-203
    5. Peter D. Brown, Mark Whittaker
      Pages 205-223
    6. Purna Mukherjee, Jin-Rong Zhou, Alexander V. Sotnikov, Steven K. Clinton
      Pages 237-261
    7. Taturo Udagawa, Henk M. W. Verheul, Robert J. D’Amato
      Pages 263-274
  4. In Vivo Studies and Clinical Trials

    1. Front Matter
      Pages 275-275
    2. Giampietro Gasparini, Adrian L. Harris
      Pages 317-339
    3. John L. Clifford, Joseph M. Miano, Scott M. Lippman
      Pages 355-370
    4. William D. Figg, James M. Pluda, Oliver Sartor
      Pages 371-383
    5. Deborah M. Milkowski, Rachelle A. Weiss
      Pages 385-398
    6. Henrik S. Rasmussen
      Pages 399-405
    7. William D. Figg, Eddie Reed, Shawn Green, James M. Pluda
      Pages 407-422
    8. Anton Wellstein, Anke M. Schulte, Claudius Malerczyk, Anne T. Tuveson, Achim Aigner, Frank Czubayko et al.
      Pages 423-441
  5. Back Matter
    Pages 443-450

About this book


In Antiangiogenic Agents in Cancer Therapy, Beverly Teicher and a panel of distinguished investigators survey the state-of-the-art of antiangiogenesis research from the lab bench to clinical trials. Timely and authoritative, the contributors summarize our current understanding of tumor growth and its dependence on vascular development, as well as the present status of antiangiogenic agents in preclinical and clinical development. In addition, the book also examines what is known about the mechanisms by which these therapeutic agents interfere with tumor vasculature and grapples with the problem of establishing criteria by which to assess their clinical efficacy.
Antiangiogenic Agents in Cancer Therapy offers a unique cutting-edge compendium of antiangiogenic research, taking stock of what has been accomplished, where the experimental therapeutics of antiangiogenic agents are going, and the continuing evolution of their role in cancer treatment and novel drug development. Comprehensive and up-to-date, this book constitutes a key resource-rich in novel means and methods-for the clinical development of this important, highly promising new class of anticancer drugs.


angiogenesis cancer cancer treatment clinical trial interferon macrophages tumor tumor growth tumor progression

Editors and affiliations

  • Beverly A. Teicher
    • 1
  1. 1.Lilly Research LaboratoriesLilly Corporate CenterIndianapolisUSA

Bibliographic information

Industry Sectors
Health & Hospitals
Oncology & Hematology